# US 2018/0022763 A1 · Anti-Viral Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022763 A1
- Document ID: US20180022763A1
- Status: Published application
- Kind: A1
- Application number: 15/588,037
- Filed: 2017-05-05
- Published: 2018-01-25
- Earliest claimed: 2015-09-02
- Assignees: AbbVie Inc.
- Applicants: AbbVie Inc.
- Inventors: Jaclyn Chau; Hui-Ju J. Chen; David A. DeGoey; John Hartung; Nathan Ide; Vikram Kalthod; Allan C. Krueger; Yi-Yin Ku; Tongmei Li; John T. Randolph; Rolf Wagner; Geoff T. Halvorsen; Christopher C. Marvin; Eric Voight; Brian S. Brown; Steven R. Martinez; Anurupa Shrestha; Howard R. Heyman
- Web page: https://patentgrep.com/patent/US20180022763A1

## CPC

- C07F 9/08: Esters of oxyacids of phosphorus {(C07F9/062 takes precedence)}
- A61P 31/14: for RNA viruses
- C07F 9/6512: having the nitrogen atoms in positions 1 and 3
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A compound of Formula VII″, or a pharmaceutically acceptable salt thereof
wherein,
X is selected from the group consisting of O and C═CH2;
R1 and R2 are independently selected from the group consisting of F, Cl, Br, CH3, CHF2 and CCH,
R3, R4 and R5 are independently selected from the group consisting of H, D, F, N3, OCH3, CN, OH, 1H-tetrazol-5-yl, 2H-tetrazol-2-yl, 1H-tetrazol-1-yl, 1H-imidazol-1-yl, 1H-imidazol-2-yl and 1H-imidazol-5-yl; and
P1 is selected from a group consisting of:

### Claim 17 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein R1 is Br and R2 is F or R1 is Cl and R2 is F.

### Claim 18 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein R1 is Br and R2 is F.

### Claim 19 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein R3 is OH and R4 is H.

### Claim 20 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein R3 is OH

### Claim 21 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein X is O.

### Claim 22 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein R5 is selected from a group consisting of H, D, F, N3, OCH3, CN, OH, 1H-tetrazol-5-yl, 2H-tetrazol-2-yl, 1H-tetrazol-1-yl, 1H-imidazol-1-yl, 1H-imidazol-2-yl and 1H-imidazol-5-yl.

### Claim 23 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from a group consisting of:
(S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-4-bromo-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino) propanoate,
(S)-isopropyl 2-(((S)-(((2R,3R,4S,5R)-4-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoateethyl 2-(((R)-(((2R,3R,4S,5R)-4-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate,
ethyl 2-(((((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate,
ethyl 2-(((((2R,3R,4R,5R)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate,
ethyl 2-(((((2R,3R,5R)-4,4-dichloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate, and
(S)-isopropyl 2-(((S)-(((2R,3R,4S,5R)-4-bromo-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl) amino)propanoate.

### Claim 24 (depends on 16)

The compound of claim 16, where said compound is (S)-isopropyl 2-(((S)-(((2R,3R,4S,5R)-4-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 16)

The compound of claim 16, where said compound is Ethyl 2-(((((2R,3R,4R,5R)-4-bromo-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate, or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 16)

The compound of claim 16, where said compound is Ethyl 2-(((R)-(((2R,3R,4R,5R)-4-bromo-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate, or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 16)

The compound of claim 16, where said compound is Ethyl 2-(((S)-(((2R,3R,4R,5R)-4-bromo-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate, or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 16)

The compound of claim 16, where said compound is Ethyl 2-(((S)-(((2R,3R,4S,5R)-4-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)-2-methylpropanoate, or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 16)

A method for treating HCV, comprising administering a compound or salt of claim 16 to a patient infected with Hepatitis C Virus.

### Claim 30 (depends on 22)

A method for treating HCV, comprising administering a compound or salt of claim 22 to a patient infected with Hepatitis C Virus.

### Claim 31 (depends on 16)

A pharmaceutical composition comprising a compound or salt of claim 16.

### Claim 32 (depends on 23)

A pharmaceutical composition comprising a compound or salt of claim 23.
